UCB Pharma v. Annora Pharma: Consent Judgment in 247 Days
UCB Pharma GmbH and UCB Biopharma SRL brought a patent infringement action against Annora Pharma Private Ltd in the Delaware District Court, asserting US6911461B2 covering 2-oxo-1-pyrrolidine derivatives. The parties reached a negotiated settlement and consented to entry of judgment and an injunction, resolving the case in 247 days.
UCB's pyrrolidine derivative patent enforced via agreed injunction
UCB Pharma GmbH and UCB Biopharma SRL (collectively UCB) filed suit against Annora Pharma Private Ltd on 6 March 2023 in the Delaware District Court before Judge Colm F. Connolly. The action asserted US6911461B2, a patent covering 2-oxo-1-pyrrolidine derivatives, their preparatory processes, and their uses — a pharmaceutical compound class with established therapeutic relevance. Annora Pharma, an India-headquartered generic pharmaceutical developer, was named as the sole defendant.
The case closed on 8 November 2023, 247 days after filing. The recorded basis of termination is Consent Judgment. The docket order states that UCB and Annora agreed to terms and conditions set out in a Settlement Agreement, and that the parties stipulated and consented to entry of both a judgment and an injunction. The specific terms of the Settlement Agreement are not disclosed in the available record.
Resolution in under nine months — without any recorded defendant counsel filing or defendant law firm on the docket — suggests Annora did not mount a substantive defence before the parties moved to settlement. Whether the consent judgment reflects a licensing arrangement, a market entry restriction, or other commercial terms is not determinable from the public record. The injunction component signals that UCB secured court-enforceable relief beyond a mere dismissal.
See Complete Case & Patent Analysis →Filing to Consent Judgment in 247 days
Days from filing to consent judgment — a relatively swift resolution for Delaware pharmaceutical patent litigation
US6911461B2 — 2-oxo-1-pyrrolidine derivatives and their uses
Any pharmaceutical developer — generic, specialty, or biosimilar — working with 2-oxo-1-pyrrolidine derivative compounds, their preparation processes, or downstream uses should treat US6911461B2 as a material FTO risk. UCB has demonstrated, in this case, that it will pursue litigation and seek court-entered injunctive relief against generic entrants. ANDA filers and development-stage companies in this chemical space face particular exposure.
Official order — verbatim text
The consent judgment records that UCB and Annora agreed to settlement terms set out in a non-public Settlement Agreement, and jointly stipulated to entry of a judgment and an injunction. The injunction component elevates this beyond a standard agreed dismissal — it creates a court-enforceable order whose scope and duration are not disclosed in the available record.
Consent judgment: what the agreed resolution means for both parties
A court-entered judgment on negotiated terms — binding and final
A consent judgment is a formal court order reflecting terms agreed by the parties. Unlike a voluntary dismissal, it carries the full force of a judicial judgment and can be enforced by the court. Here, the parties stipulated to entry of both a judgment and an injunction, meaning the court's retained jurisdiction covers enforcement of the injunctive terms. The underlying Settlement Agreement is not publicly disclosed.
Binding court orderUCB secures an injunction — court-enforceable protection for US6911461B2
UCB obtained a court-entered injunction against Annora, providing an enforceable mechanism to restrain future infringing conduct. The consent judgment preserves the validity and enforceability of US6911461B2 without the uncertainty of a full trial. The specific scope of the injunction and any licensing or commercial terms are not disclosed in the available record.
Injunction grantedAnnora consents to judgment and injunction — no public defence mounted
No defendant counsel or law firm appears on the docket, and the case resolved in under nine months, suggesting Annora did not contest the claims before agreeing to settlement. By consenting to judgment, Annora accepted court-binding terms. What, if any, rights or market access terms Annora may have received under the Settlement Agreement is not disclosed in the available record.
Consented to judgmentPyrrolidine derivative IP enforced — a signal to other generic entrants
A consent judgment with an injunction in a pharmaceutical patent case in Delaware sends a clear enforcement signal to other generic developers working in the 2-oxo-1-pyrrolidine derivatives space. UCB demonstrated willingness to litigate and secure court-entered relief. Generic and specialty pharma companies with ANDA or development programmes touching this compound class should assess FTO exposure against US6911461B2.
Enforcement signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | UCB Pharma, Gmbh | Company | /Search in Eureka ↗ |
| Co-Plaintiff | UCB Biopharma, SRL | Company | Search in Eureka ↗ |
| Defendant | Annora Pharma Private, Ltd. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff counsel | Karen Jacobs | Attorney | Counsel for UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing UCB Pharma, GmbhSearch in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the 2-oxo-1-pyrrolidine derivatives IP space
Forward-looking patent and R&D intelligence derived from UCB's enforcement of US6911461B2 — covering portfolio trends, competitive filings, and white-space opportunities in the pyrrolidine derivative space.
UCB's pyrrolidine and CNS patent filing activity
UCB's enforcement of US6911461B2 suggests this patent sits within a broader pyrrolidine and CNS-focused portfolio. Mapping UCB's subsequent filings in this compound class can reveal whether newer patents extend or reinforce protection beyond the original application date — a critical input for generic developers assessing long-term FTO.
UCB portfolio watchPatent filing trends around 2-oxo-1-pyrrolidine derivatives
The 2-oxo-1-pyrrolidine scaffold underpins multiple pharmaceutical applications. Tracking global patent filings in this chemical class — including preparation process innovations and new use claims — can identify where the competitive frontier is moving and which jurisdictions are seeing the highest filing activity from generic and innovator companies alike.
Compound class trendsAnnora Pharma's patent and R&D position in pyrrolidine chemistry
Annora Pharma's consent to a UCB injunction without recorded defence counsel raises questions about the depth of its own IP position in this space. Reviewing Annora's patent filings and ANDA activity in pyrrolidine-related compounds can indicate whether the company is developing design-around strategies or repositioning its generic pipeline away from this chemical class.
Annora IP watchAdjacent opportunities near the pyrrolidine derivative patent landscape
Despite UCB's strong position in 2-oxo-1-pyrrolidine derivatives, adjacent structural modifications and alternative synthesis processes may represent patentable white space. Identifying claim gaps in the existing landscape — including expired prior art and unpatented preparation routes — can guide R&D investment toward defensible, differentiated positions in this chemical domain.
IP white spaceSimilar pharmaceutical patent consent judgment cases in Delaware
Explore comparable patent infringement actions in the Delaware District Court involving pharmaceutical compound patents and generic entrants resolved by consent judgment or agreed injunction.
What this case signals for the pharmaceutical patent IP landscape
UCB's swift enforcement and consent judgment in Delaware underscores active policing of pyrrolidine derivative IP against generic entrants.
Delaware remains the jurisdiction of choice for pharma patent enforcement
UCB filed in Delaware, consistent with the court's established expertise in Hatch-Waxman and pharmaceutical patent disputes. The case resolved quickly — 247 days — with an injunction, reinforcing Delaware's value as a plaintiff-friendly forum for obtaining enforceable relief without prolonged litigation.
Consent judgment with injunction raises the bar for generic competition
The court-entered injunction against Annora goes beyond a mere dismissal. Other generic developers in the 2-oxo-1-pyrrolidine derivatives space should treat this outcome as evidence that UCB will seek injunctive relief, not just damages, and that early settlement may not avoid injunctive exposure.
UCB v Annora — key questions answered
The case ended by consent judgment on 8 November 2023, 247 days after filing. UCB Pharma GmbH, UCB Biopharma SRL, and Annora Pharma Private Ltd agreed to settlement terms and jointly stipulated to entry of a judgment and an injunction. The specific terms of the Settlement Agreement are not disclosed in the available record.
UCB asserted US6911461B2, which covers 2-oxo-1-pyrrolidine derivatives, processes for preparing them, and their uses. The application number on record is US10/693917. The patent was asserted in an infringement action filed on 6 March 2023 in the Delaware District Court.
By consenting to judgment, Annora accepted a court-binding order that includes an injunction. This means the court retains jurisdiction to enforce compliance. The scope of the injunction and any commercial or licensing terms agreed between the parties are not disclosed in the publicly available record.
Delaware is a frequently used forum for pharmaceutical patent enforcement, including Hatch-Waxman litigation, due to the court's established expertise in complex patent cases. Judge Colm F. Connolly presided over this matter. No specific venue rationale is stated in the available case record beyond the Delaware District Court filing.
US6911461B2 covers 2-oxo-1-pyrrolidine derivatives, their preparation processes, and their uses — a broad scope that extends beyond finished formulations to synthesis routes and compound intermediates. UCB's enforcement of this patent, culminating in a consent judgment with injunction, demonstrates active policing. Generic and specialty pharma developers in this chemical space should conduct FTO analysis before committing to development or ANDA filing.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.